And that brings us to the point that with EBITDA at €2.0M this year, it would only rise to €2.1M next year, despite expectations of strong revenue growth and the fact that high-margin pay-per-treatment (PPT) revenue is already at €2M/year. The comments (which should be taken with a grain of salt) also pointed toward more products starting to ship instead of just development projects.
Add to this the reduced financing risks brought by the growth in cash flow, and I certainly see Modulight’s situation as considerably more positive than at any point over the last couple of years. Of course, this remains very sensitive to business fluctuations, and the risks in both directions are high.